Loading...

OCGN OCUGEN INC US FDA Inspections 8-K Filing

CGN

CGN

OCUGEN INC

(OCGN)

2023 8-K

Show Summary

Show Summary

Investor Meetings

Financial Statements

Investor Presentation

Financial Results

Investor Presentation

Investor Presentation

Loan Agreement Update

Investor Presentation

Investor Presentation

Management Change

Investor Presentation

Financial Results

Investor Presentation

FDA Notification for Expand...

Public Offering

Appointment of Pricewaterho...

Accounting Firm Change

Financial Results Announcement

Dividend Declaration

Litigation Dismissal

FDA Clearance for Phase 3 T...

Restatement of Financial St...

Litigation Dismissal

Departure of Directors and ...

Presentation at Clinical Sh...

Other Special Situation

Appointment of Interim Chie...

Clinical Study Update

Management Changes

Annual Meeting Results

Presentation at BIO Interna...

Underwriting Agreement

Results of Operations and F...

Positive Preliminary Data a...

Resignation of Chief Accoun...

Appointment and Lawsuit Dis...

Other Special Situation

External Links:

Ocugen received alignment from the FDA on key aspects of the Phase 3 clinical trial design for OCU400 in patients with Retinitis Pigmentosa.

AI Assistant

OCUGEN INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.